2022
Expression and Potential Prognostic Value of SOX9, MCL-1 and SPOCK1 in Gastric Adenocarcinoma
Luo W, Nagaria T, Sun H, Ma J, Lombardo J, Bassett R, Cao A, Tan D. Expression and Potential Prognostic Value of SOX9, MCL-1 and SPOCK1 in Gastric Adenocarcinoma. Pathology & Oncology Research 2022, 28: 1610293. PMID: 35221802, PMCID: PMC8863590, DOI: 10.3389/pore.2022.1610293.Peer-Reviewed Original ResearchConceptsGastric cancerPrognostic valueGastric adenocarcinomaMcl-1Pathologic TNM stageDifferent treatment modalitiesCancer-related deathPotential prognostic valueFurther subgroup analysisNegative prognostic markerTumor heterogeneityDifferent molecular alterationsSOX9 expressionSPOCK1 expressionPrognostic roleCommon malignancyPoor prognosisTNM stageTreatment modalitiesSubgroup analysisPrognostic markerUnivariate analysisDisease prognosisDivergent differentiationMolecular alterations
2019
Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab
Zhang H, Luo W, Wang Y. Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab. Journal For ImmunoTherapy Of Cancer 2019, 7: 47. PMID: 30777137, PMCID: PMC6380028, DOI: 10.1186/s40425-019-0532-1.Peer-Reviewed Original ResearchConceptsImmune-related adverse reactionsGrade 3 colitisGastrointestinal reactionsLiver injuryClinical historyImmune checkpoint inhibitor-related colitisBackgroundImmune checkpoint inhibitorsElevated liver enzymesPD-1 inhibitorsTNF-α agentsAcute liver injuryInflammatory bowel diseaseOne-time infusionInfliximab therapyAcute hepatitisCheckpoint inhibitorsRescue therapyAdvanced malignanciesBiologic agentsBowel diseaseLiver profileCase presentationWePatient populationCTLA-4Final diagnosis